Cebranopadol reduced pain intensity in patients following abdominoplasty surgery in the ALLEVIATE-1 clinical trial.
The following is a summary of “Repetitive Transcranial Magnetic Stimulation for the Treatment of Complex Regional Pain Syndrome: A Pilot Study,” published in the January 2025 issue of Pain by Foglia ...
The following is a summary of “Pain Assessment and Management in Oncological Practice: A Survey from the Italian Network of ...
The new data comes from the phase 3 ALLEVIATE-1 trial, which compared cebranopadol to placebo for the management of ...
GlobalData on MSN2d
Tris Pharma reports positive data from Phase III acute pain therapy trialTris Pharma has reported positive topline outcomes from its ALLEVIATE-1 Phase III trial of cebranopadol for treating moderate ...
ZME Science on MSN1d
Researchers made an AI feel pain, because what could go wrong?What could possibly go wrong with giving machines a taste of suffering? It's not like they'd take over the world or something ...
Physician empathy has long been recommended — but not required — in the doctor-patient relationship.However, for a growing ...
Vertex Pharmaceuticals (NASDAQ: VRTX) might be one of those special cases. Should you buy Vertex stock hand over fist before ...
Further endpoints included improvements in back pain (Numeric Rating Scale [NRS] scores), spinal stiffness, functional ...
Mainstay Medical Holdings announces outcomes from RESTORE clinical trial of ReActiv8 to treat intractable chronic low back pain: Dublin, Ireland Saturday, January 18, 2025, 18:00 ...
Mainstay Medical Holdings plc today announced the publication of positive one-year primary assessment results of the RESTORE randomized clinical trial of ReActiv8 for the treatment of intractable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback